|
|
|
Amorfix Launches Alzheimer's Amyloid Test at Scientific Conference in Vienna
Test Can Quantitatively Measure Amyloid Months Earlier Than Current Microscopic Approach
|
Toronto, July 16, 2009 - Amorfix Life Sciences, a company focused on treatments and diagnostics for brain wasting diseases is presenting a paper at the International Conference on Alzheimer's Disease (ICAD2009) entitled "A(4): An Ultrasensitive Method for the Detection of Aggregated beta-Amyloid". The hallmark of Alzheimer's disease (AD) is the aggregation and accumulation of beta-amyloid as plaques in the brain. The A(4) assay can detect beta-amyloid in standard animal models of AD several months before conventional microscopic procedures and hence can accelerate the preclinical screening of new drugs for AD. In addition, the assay is significantly more sensitive than current methods for detecting total Abeta and can be used in high-through-put applications designed to study the inhibition of amyloid formation.
"We are very pleased with the initial response from the pharmaceutical and academic communities to our amyloid testing service," said Dr. George Adams, Chief Executive Officer of Amorfix. "There are over 300 companies and thousands of researchers studying AD and seeking new treatments, who could benefit from this sensitive and specific test for beta-amyloid."
Last year, there were over 5,400 attendees at ICAD2008. Amorfix will be accepting orders for the testing service from researchers who wish to characterize the rate of beta-amyloid formation in animals or tissue culture at its Exposition Booth number 327.
For More Information Contact :
Dr. George Adams
President & Chief Executive Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6959
Fax: (416) 847-6899
george.adams@amorfix.com
------------------------------------
Publish your news!
Write to us at :
news@chrgonline.com
|
|
|
|
